Iron chelation therapy in sickle cell disease
- 31 January 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 69-72
- https://doi.org/10.1016/s0037-1963(01)90062-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Combined therapy with deferiprone and desferrioxamineBritish Journal of Haematology, 1998
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- Iron-balance and dose-response studies of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell diseaseBlood, 1994
- Rapid removal of excessive iron with daily, high-dose intravenous chelation therapyThe Journal of Pediatrics, 1989
- Depletion of excessive liver iron stores with desferrioxamineBritish Journal of Haematology, 1984
- DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJORThe Lancet, 1984
- Iron chelation therapy in sickle cell anemiaAmerican Journal of Hematology, 1979
- Excretion of iron in response to deferoxamine in sickle cell anemiaThe Journal of Pediatrics, 1978
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974